Fundraising Fox

Serapha Bio

1 known investors

Serapha Bio is a biotechnology company. It has announced a merger agreement with Boundless Bio alongside a $230 million concurrent private placement.

Biotech

Investors · 1

Vivo CapitalPalo Alto · $10M – $50M

In the news

Alpha-1 Antitrypsin Gene Editing Startup Raises $230 Million: Serapha Bio AATD Debuttechtimes.com · Jun 2026Gene Therapy Startup Targets 100,000 AATD Patients: Serapha Bio Launches With $230Mtechtimes.com · Jun 2026Boundless Bio Merges with Serapha Bio - BOLD | BioPharmaWatchbiopharmawatch.com · Jun 2026Serapha Bio Launches with $230M to Advance In Vivo Base Editing Therapy for Alpha-1 Antitrypsin Deficiency | PackGene Biotechpackgene.com · Jun 2026Gene-editing startup Serapha launches with $230M, Chinese licensing dealstatnews.com · Jun 2026

Frequently asked questions

What does Serapha Bio do?
Serapha Bio is a biotechnology company. It has announced a merger agreement with Boundless Bio alongside a $230 million concurrent private placement.
Who are Serapha Bio's investors?
Serapha Bio's investors include Vivo Capital.